Skip to main content

Fiscal Wizard · Single-issue tearsheet

ZVRA / Jun 21, 2026 Run #7344

ZVRA

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Composite verdict

A 81.7 / 100
Bullish setup · Trend Following 17 drivers · 3 gates blocking
  • Chaikin Money Flow
  • Relative Strength vs SPY
  • Stochastic RSI
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 15th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile uptrend
Bull 100%Evidence: High · 21 signals0% Bear
Momentum Bullish 95Mean-reversion Neutral 54
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
  • Late-stage trendTrend signals have been live for 77 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -61%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Above average

63.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Return on Assets 92
OCF to Net Income 0
Greenblatt ROC 90
Free Cash Flow Yield 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Chaikin Money Flow, Relative Strength vs SPY, Stochastic RSI); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 97
Relative Strength vs SPY 94
Rate of Change 92

Risk Gates

3 blocking 7 caution

3 guards active, 20 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ZVRA.